LGND Exercise Disclosure
Reardon Andrew · SEC Form 4 · Filed Nov 4, 2026
Exercise
Calculated transaction value
$0
Reardon Andrew CLO & Secretary
LGND
Transaction date
Nov 2, 2026
Public filing date
Nov 4, 2026
Filing lag
Filed 2 days later
LGND daily price context
Close on/before transaction
$307.02
Nov 2, 2026
First close after public filing
--
Unavailable
30-day return after filing
--
Through Unavailable
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Employee Stock Option (right to buy) on Common Stock
- Quantity / price
- 5,000 shares @ $0
- SEC ownership
- Direct
- Transaction code
- M
- Form
- 4
- Filing identifier
- 0001950232-26-000006
Filing cohort
Transactions in this filing
Showing 15 of 15
Trades
15
Issuers
1
Estimated value
$1.83M
Buys / sales
0 / 13
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $86.99K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $218.37K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $64.29K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $38.78K |
| Ligand Pharmaceuticals Inc LGND Current | Exercise | Nov 2, 2026 | $0 |
| Ligand Pharmaceuticals Inc LGND | Exercise | Nov 2, 2026 | $261.35K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $161.77K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $152.2K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $162.09K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $198.35K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $25.17K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $89.01K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $140.24K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $102.39K |
| Ligand Pharmaceuticals Inc LGND | Sale | Nov 2, 2026 | $126.44K |